Guardian Pharmacy Services vs Omnicell
GRDN and OMCL side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRDN and OMCL compare
Guardian Pharmacy Services is the larger company, worth 2.0 times as much as Omnicell ($3.2B against $1.6B).
Omnicell grew revenue faster over the last twelve months (5.6% versus 4.9% for Guardian Pharmacy Services).
Guardian Pharmacy Services keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with 3.6% at Omnicell.
Omnicell scores higher on the StockData Score (13 against 9 for Guardian Pharmacy Services), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRDN | OMCL |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $1.6B |
| Share price | $49.98 | $35.57 |
| Change, 1 year | 68.0% | −3.4% |
| Change, 5 years | – | −80.6% |
| Beta (5Y) | 0.56 | 0.83 |
| Employees | 3,600 | 3,580 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 36.7× |
| P/S | 2.2× | 1.3× (better) |
| P/B | – | 1.2× |
| EV/EBITDA | 26.0× | 9.3× (better) |
| P/FCF | – | 11.1× |
| FCF yield | – | 9.0% |
| Fair value | $19.44 | $54.32 |
| Margin of safety | −157% | 34.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.9% | 5.6% (better) |
| Revenue growth, 5Y average | – | 5.8% |
| Net income growth (TTM) | 85.8% | 124% (better) |
| EPS growth (TTM) | – | 126% |
| EPS growth, 5Y average | – | −44.2% |
| Profitability | ||
| Gross margin | 22.4% | 45.1% (better) |
| Operating margin | 6.5% (better) | 5.2% |
| Net margin | 5.1% (better) | 3.6% |
| FCF margin | – | 11.7% |
| Return on equity | – | 3.5% |
| Return on invested capital | – | 4.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 145× | – |
| Current ratio | 1.65 | 1.66 (better) |
| Altman Z-score | 13.18 (better) | 2.50 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Buyback yield | −0.96% | – |
| Shareholder yield | −0.96% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 46.6% | 106% |
| Held by insiders | 43.6% | 3.3% |
| Insider net buying, 12 months | −$419M | −$2.9M (better) |
| Short interest, % of float | 6.2% | 8.6% |
Go deeper
- GRDN stock overview
- GRDN income statement
- GRDN valuation and score
- OMCL stock overview
- OMCL income statement
- OMCL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.